Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18726901 | 0.89 | HTT (0.33) | ACP1TMPRSS4AR | |
| SCHEMBL18856804 | 0.88 | — | — | |
| SCHEMBL15544207 | 0.86 | TMPRSS4 (0.36) | ACP1TMPRSS4AR | |
| SCHEMBL15544204 | 0.86 | TMPRSS4 (0.36) | ACP1TMPRSS4AR | |
| SCHEMBL18856832 | 0.83 | MEN1 (0.30) | — | |
| SCHEMBL16471301 | 0.82 | NPC1 (0.32) | — | |
| SCHEMBL16471346 | 0.80 | — | — | |
| SCHEMBL18723686 | 0.80 | ACP1 (0.33) | ACP1TMPRSS4AR | |
| SCHEMBL16471329 | 0.80 | KDR (0.33) | TMPRSS4AR | |
| SCHEMBL15544863 | 0.77 | MAP2K1 (0.34) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9511059-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511059-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150353511-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353511-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-10 | — | — | US | disclosed |
| WO-2014135471-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| US-20140242028-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242028-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014114573-A1 | ANTIVIRAL TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ACP1 4418/4885TMPRSS4 1031/4885AR 4500/4885 |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ACP1 4418/4885TMPRSS4 1031/4885AR 4500/4885 |
| US-20140242028-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ACP1 4522/4885TMPRSS4 1166/4885AR 4573/4885 |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ACP1 4522/4885TMPRSS4 1166/4885AR 4573/4885 |
| US-20150353511-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ACP1 4522/4885TMPRSS4 1166/4885AR 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.